Wells Fargo Maintains Overweight on Biogen, Raises Price Target to $310

Benzinga · 2d ago
Wells Fargo analyst Mohit Bansal maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $250 to $310.